Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) Investor Securities Class Action Lawsuit 07/29/2019

If you purchased shares of Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM), you have certain options and for certain investors are short and strict deadlines running. Deadline: September 27, 2019. NASDAQ: OASM investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Oasmia Pharmaceutical
Case Name: 
Oasmia Pharmaceutical Shareholder Class Action Lawsuit 07/29/2019
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: OASM
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
07/29/2019
Class Period Begin: 
10/23/2015
Class Period End: 
07/09/2019
Court of Filing: 
U.S. District Court for the Eastern District of New York
Deadline To File for Lead: 
09/27/2019
Summary: 

An investor in shares of Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) filed a lawsuit in the U.S. District Court for the Eastern District of New York over alleged violations of Federal Securities Laws by Oasmia Pharmaceutical AB in connection with certain allegedly false and misleading statements made between October 23, 2015 through July 9, 2019.

Sweden based Oasmia Pharmaceutical AB develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. On July 9, 2019, post-market, Oasmia reported that it had terminated its “engagement and cooperation” with former executive chairman Julian Aleksov without further pay, following a tax audit that revealed missing funds connected to suspicious transactions between Oasmia and companies controlled by Aleksov and his former father-in-law. Shares of Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) declined from $5.06 per share in November 2018 to as low as $1.78 per share on July 11, 2019.

According to the complaint the plaintiff alleges on behalf of purchasers of Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) common shares between October 23, 2015 through July 9, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 23, 2015 through July 9, 2019, the defendants made false and/or misleading statements and/or failed to disclose that Oasmia engaged in improper related-party transactions with Alceco International S.A. and Ardenia Investment LTD, which were controlled by Defendant Aleksov and his former father-in-law, that due to those transactions, millions of Swedish kronor were not accounted for in Oasmia's books;, that transactions concerning Oasmia's patents were also "carried out in a doubtful way;" and that as a result of the aforementioned misconduct, defendants' statements about Oasmia's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.